Toggle light / dark theme

Looking to study neurological conditions, researchers produce over 400 different types of nerve cells

Nerve cells are not just nerve cells. Depending on how finely we distinguish, there are several hundred to several thousand different types of nerve cells in the human brain, according to the latest calculations. These cell types vary in their function, in the number and length of their cellular appendages, and in their interconnections. They emit different neurotransmitters into our synapses, and depending on the region of the brain—for example, the cerebral cortex or the midbrain—different cell types are active.

When scientists produced from in Petri dishes for their experiments in the past, it was not possible to take their vast diversity into account. Until now, researchers had only developed procedures for growing a few dozen different types of nerve cell in vitro. They achieved this using or by adding signaling molecules to activate particular cellular signaling pathways. However, they never got close to achieving the diversity of hundreds or thousands of different nerve cell types that actually exist.

“Neurons derived from stem cells are frequently used to study diseases. But up to now, researchers have often ignored which precise types of neuron they are working with,” says Barbara Treutlein, Professor at the Department of Biosystems Science and Engineering at ETH Zurich in Basel.

Precision at the smallest scale

Imagine a high-tech workshop where scientists and engineers craft objects so small they can’t be seen with the naked eye — or even a standard microscope. These tiny structures — nanostructures — are thousands of times smaller than a strand of hair. And they are essential for faster computers, better smartphones and life-saving medical devices.

Nanostructures are at the core of the research happening every day in the Washington Nanofabrication Facility (WNF). Part of the Institute for Nano-Engineered Systems at the UW and located in Fluke Hall, the WNF supports cutting-edge academic and industry research, prototyping and hands-on student training. Like many leading nanofabrication centers, it is part of the National Science Foundation’s National Nanotechnology Coordinated Infrastructure, a network that shares expertise and resources.


Step inside the Washington Nanofabrication Facility, where tiny tech is transforming research in quantum, chips, medicine and more.

Scientists create biological ‘artificial intelligence’ system

Australian scientists have successfully developed a research system that uses ‘biological artificial intelligence’ to design and evolve molecules with new or improved functions directly in mammal cells. The researchers said this system provides a powerful new tool that will help scientists develop more specific and effective research tools or gene therapies.

Named PROTEUS (PROTein Evolution Using Selection) the system harnesses ‘directed evolution’, a lab technique that mimics the natural power of evolution. However, rather than taking years or decades, this method accelerates cycles of evolution and natural selection, allowing them to create molecules with new functions in weeks.

This could have a direct impact on finding new, more effective medicines. For example, this system can be applied to improve gene editing technology like CRISPR to improve its effectiveness.

BCI robotic hand control reaches new finger-level milestone

As detailed in a new study in Nature Communications, He’s lab brings noninvasive EEG-based BCI one step closer to everyday use by demonstrating real-time brain decoding of individual finger movement intentions and control of a dexterous robotic hand at the finger level.

“Improving hand function is a top priority for both impaired and able-bodied individuals, as even small gains can meaningfully enhance ability and quality of life,” explained Bin He, professor of biomedical engineering at Carnegie Mellon University. “However, real-time decoding of dexterous individual finger movements using noninvasive brain signals has remained an elusive goal, largely due to the limited spatial resolution of EEG.”

Clinical test predicts best rheumatoid arthritis treatment on first try

1 in 100 people in Britain today live with rheumatoid arthritis (RA). Unlike osteoarthritis (OA), RA is caused not by wear and tear but by the body’s immune system attacking its own joints. RA can strike quickly at any age—but is most common for people aged 40–60.

Biological therapies are the leading treatment. Clinicians use engineered proteins made from living cells to slow the disease by targeting the specific parts of the immune system that are going rogue. Over the past 20 years they have led to major improvements in helping patients to live with RA.

However, different patients will react differently to different biological therapies depending upon their genetics. This means individual therapies have a failure rate of approximately 40%.

AI helps discover optimal new material for removing radioactive iodine contamination

Managing radioactive waste is one of the core challenges in the use of nuclear energy. In particular, radioactive iodine poses serious environmental and health risks due to its long half-life (15.7 million years in the case of I-129), high mobility, and toxicity to living organisms.

A Korean research team has successfully used artificial intelligence to discover a new material that can remove iodine for nuclear environmental remediation. The team plans to push forward with commercialization through various industry–academia collaborations, from iodine-adsorbing powders to contaminated water treatment filters.

Professor Ho Jin Ryu’s research team from the Department of Nuclear and Quantum Engineering, in collaboration with Dr. Juhwan Noh of the Digital Chemistry Research Center at the Korea Research Institute of Chemical Technology, developed a technique using AI to discover new materials that effectively remove contaminants. Their research is published in the Journal of Hazardous Materials.

Lab-grown ‘tiny hearts’ bring hope for children and adults with genetic heart disease

Scientists from QIMR Berghofer’s Cardiac Bioengineering Lab have developed lab-grown, three-dimensional heart tissues known as cardiac organoids that mimic the structure and function of real adult human heart muscle.

To create these tissues, the researchers use special cells called (which can turn into any cell in the body). However, when these stem cells become , they usually stay immature and more like the heart tissue found in a developing baby. This immaturity can limit their usefulness to model diseases that present in childhood or as an adult.

In the study, researchers activated two key biological pathways to mimic the effects of exercise in order to mature these cells, making them behave more like genuine adult heart tissue. This breakthrough means scientists can now use these lab-grown heart tissues to test that could help people with heart conditions. The findings have been published in Nature Cardiovascular Research.

Engineered protein can turn off tissue-damaging immune cells in autoimmune diseases

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, multiple sclerosis, shows a new study in mice.

In these autoimmune diseases, T cells mistakenly target the body’s own tissues instead of invading viruses or bacteria as they would during normal immune responses. Treatments focused on T cells have been elusive because blocking their action broadly weakens the immune system and creates risk for infections and cancer.

Published online June 30 in the journal Cell, the study revealed that holding closely together two protein groups (signaling complexes) on T cells, including one found more often on T cells involved in autoimmune disease, shuts down those T cells in a limited way.